Auf zu alten Höhen? - 500 Beiträge pro Seite

[Gustl24]

die amerikanischen boards sind sehr bullish bzgl.
SNBP...ich könnte mir vorstellen, dass die volumina
stark zunehmen...we will see

könnte mir jemand bei material, RT chart etc.
"zur hand" gehen...

vielen dank

hab z.zt. viel arbeit

[Gustl24]

mal was zum einlesen:

Sinobiopharma has Production Rights to 23 Drugs Listed in China's National Essential Drugs List

All Drugs on List to be Covered by Basic Government Insurance That Will Cover 90 Percent of China's Population
NANTONG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce that 23 generic drugs for which the Company has production rights are listed in China's National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.

According to the Chinese government's healthcare reform plan, 90 percent of China's citizens will be covered by a universal healthcare system by the year 2010. Under the plan, drugs on the National Essential Drugs List (the "List") will be purchased by various levels of government first, then distributed to medical facilities. All drugs on the List will be covered by the basic insurance plan supported by the government. The plan also calls for medical facilities to be upgraded, which includes the construction of 30,000 new hospitals, clinics and care centers across China.

"While Sinobiopharma is primarily focused on the development, production and distribution of "me-too/me-better" branded new or generic drugs with high margins, the inclusion of 23 generic drugs for which the Company owns production rights on the National Essential Drugs List, will enable us to increase both sales and margins," said Dr. Lequn Lee Huang, Sinobiopharma President and CEO. "We expect that this new advantage in the marketplace will also enable the Company to enhance our ability to improve return on investment for shareholders in 2010."

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

[Gustl24]

heute knapp 20 % z.zt. im plus...

so schlecht war der anfang nicht...

[Gustl24]

Sinobiopharma Inc.
(OTCBB: SNBP)

Financial Snapshot:

Business: Biopharma
Exchange: OTCBB
Symbol: SNBP

Sinobiopharma Inc. (OTCBB: SNBP)

Detailed Quote: http://www.otcpicks.com/quotes/SNBP.php



Company Overview

Sinobiopharma Inc. is an emerging, fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anaesthesia-assisted agents and cardiovascular drugs. Founded in 2004, Sinobiopharma employs more than 80 people at its corporate office and production facility in Nantong, China.

Sinobiopharma launched its extremely low-cost, Chinese patented new formulation of the pre-surgical skeletal muscle relaxant Cisatracurium Besylate on May 30, 2006. By October 2007, it had captured 80% of the Chinese market and was in use in more than 200 hospitals.

Anesthetics Product Pipeline

Cisatracurium besylate

Nondepolarizing skeletal muscle relaxant; indicated for inpatients and outpatients as an adjunct to general anesthesia; facilitates tracheal intubation, and provides skeletal muscle relaxation during surgery or mechanical ventilation in the ICU; approved by the SFDA in 2006.

Rocuronium

Nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration; indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Gantacurium chloride

New, investigational, non-depolarizing ultra-short acting neuromuscular blocker; used as an adjunct to general anesthesia to enable rapid intubation of patients undergoing surgery.

Cardiovascular Product Pipeline

Eplerenone

Blocker of aldosterone binding at the mineralocorticoid receptor;
indicated for congestive heart failure, post-myocardial infarction
and hypertension.

Perindopril

Non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor;
indicated for stable coronary artery disease hypertension.

Clevidipine butyrate

Dihydropyridine calcium channel blocker; indicated for the reduction of blood pressure when oral therapy is not feasible or desirable.

Revenue Forecast



Investment Highlights

Leadership of CEO, Dr. Lequn Lee Huang a former manager of the Bayer Co., one of the world's largest pharmaceutical companies
Diverse portfolio of marketed products and robust product pipeline
Proven track record of product development and commercialization
Strong financial management with CFO formerly of JP Morgan Chase and Smith Kline Beecham
Patented technology for fast, low-cost synthesis of active pharmaceutical ingredients (API) enhances capability for rapid development of new drugs
Proven R&D partners for collaborative drug discovery and established relationships with multinationals for outsourced drug development
Nationwide sales and distribution network
Patented technology for rapid low cost drug discovery
Experienced management with international track record
Flagship drug a best seller in China
Robust product pipeline and increasingly diversified portfolio
R&D Strength

Sinobiopharma conducts research and development through Nanjing Su Ji Biotech Research Development Center and in cooperation with the Medicinal Chemistry Research Institute, Nanjing University. Both are located at Nanjing University in Nanjing. The city has emerged as one of China major biotech research and development centres. Sinobiopharma's R&D team of 18 specialists (out of a total staff of 80) are highly experienced research personnel and medical professionals. They have given the Company a strong intellectual property base with six patents (see table below), primarily in the area of new methods for synthesizing compounds at lower cost, more rapidly and/or with greater ease of use. This strong R&D capacity, coupled with Sinobiopharma's established links with multinational pharmaceutical companies makes the Company an attractive partner as a contract research organization (CRO).

Growth Strategy

Sinobiopharma has a clearly defined strategy to drive short, middle and long term growth. All drug development will leverage the Company's patented technology for fast, low-cost drug synthesis and new technology for formulation.

In the Short Term, the focus is launching drugs new to the Chinese market. The Company's patented synthesis method allows the company to develop new active pharmaceutical ingredients (API) at lower cost and new formulations that generally offer greater convenience in application and efficacy with fewer side effects.

The Middle Term will focus on exporting Active Pharmaceutical Ingredients and Drug Reformulations developed with the Company's patented technology for the global market.

The Long Term will focus on applying the technology platform to identifying candidate compounds from Traditional Chinese Medicines. Such compounds have proven their safety and efficacy over thousands of years of use. Sinobiopharma will accelerate their discovery, synthesis and formulation for pharmaceutical applications.

Leverage patented technology for fast, low-cost drug synthesis and new drug formulation
Short-term focus on launching “Me-too/Me-better” drugs new to the Chinese market
Medium-term focus on exporting API’s and drug reformulations
Long-term focus on applying the technology platform to identify candidate compounds from Traditional Chinese Medicines, “Me-new”
Future Chinese “Teva” (Israel)
Competitive Advantages

Expanding in fast-growing Chinese healthcare market
Proprietary technology enables low cost, high quality API and innovative formulations for unstable drugs
Experience with Chinese FDA expedites fast approval of first-to-market (FTM) drugs
FTM drugs get higher price points and exclusivity
Integrated marketing and distribution support higher profit
Government support includes no-interest loan, tax advantages for five years, and high-tech cooperation benefit
Sales and Distribution

Nationwide Distribution Network

Sinobiopharma has an established a nationwide sales and marketing network that distributes its products in 30 provinces and key major cities throughout China. The Company intends to expand its sales and marketing infrastructure to meet China's rapidly growing demand for safer, lower-cost, higher-efficacy drugs.

[Gustl24]

das sollte fürs erste "einlesen" mal reichen...

bei interesse RT-chart usa noch in den thread reinkopieren, danke.

bin gespannt was wird...

bis bald
gustl

[Lizu]

[Lizu]

[Gustl24]

kam gerade raus...hört sich ganz solide an:

Sinobiopharma Reports Higher Revenues and Net Income
By Justin Kuepper · Friday, January 15th, 2010Sinobiopharma Inc. (SNBP), which provides enhanced generic drugs like Teva Pharmaceuticals, Inc. (TEVA) or Taro Pharmaceuticals, Inc. (TAROF), saw its revenues jump 120% as it swung to a profit for its latest quarter.

Sinobiopharma Inc. (SNBP), a manufacturer and marketer of biopharmaceutical products in China, announced earnings of $1,073,550 for the three months ended November 30, 2009, compared to a net loss of $1,045,239 during the same period a year ago.

Revenues increased 120% to $2,137,471 and gross margins that improved 182% to 80% of sales, both of which were attributed to continuing growth in the sales of Cisatracurium Besylate. The drug now represents approximately 96% of the company’s total sales.

Operating expenses decreased 63% to $596,154 due to a decrease in stock-based compensation and a reduction in general and administrative expenses. However, research and development expenses rose to $189,396 from $33,015 a year ago.

As a result, net cash from operating activities rose $804,518 to $1,124,109 compared to $319,591 for the six months ended November 30, 2008 versus November 30, 2009.

Notably, Sinobiopharma is also actively enhancing internal controls in order to improve reporting standards. In October 2009, the company engaged Xinjie Mu, a certified public accountant with extensive experience in internal control and U.S. GAAP reporting compliance, as Chief Financial Officer. These efforts should help increase investor confidence.